Drug Interactions of Clinical Importance among the Opioids, Methadone and Buprenorphine, and Other Frequently Prescribed Medications: A Review

被引：221

作者：

McCance-Katz, Elinore F. ^{[1
]}

Sullivan, Lynn E. ^{[2
]}

Nallani, Srikanth ^{[3
]}

机构：

[1] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA

[2] Yale Univ, Dept Internal Med, New Haven, CT USA

[3] US FDA, Off Clin Pharmacol, CDER, Silver Spring, MD USA

来源：

AMERICAN JOURNAL ON ADDICTIONS | 2010年 / 19卷 / 01期

关键词：

HEPATITIS-C VIRUS; CYTOCHROME-P450; 3A4; OPIATE WITHDRAWAL; N-DEMETHYLATION; HIV; PHARMACOKINETICS; INVOLVEMENT; ZIDOVUDINE; CYP3A; ANTIRETROVIRALS;

D O I：

10.1111/j.1521-0391.2009.00005.x

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Drug interactions are a leading cause of morbidity and mortality. Methadone and buprenorphine are frequently prescribed for the treatment of opioid addiction. Patients needing treatment with these medications often have co-occurring medical and mental illnesses that require medication treatment. The abuse of illicit substances is also common in opioid-addicted individuals. These clinical realities place patients being treated with methadone and buprenorphine at risk for potentially toxic drug interactions. A substantial literature has accumulated on drug interactions between either methadone or buprenorphine with other medications when ingested concomitantly by humans. This review summarizes current literature in this area. (Am J Addict 2009;19:4-16).

引用

页码：4 / 16

页数：13

共 92 条

[1] Pharmacokinetic drug interactions with nevirapine [J].

Back, D ;

Gibbons, S ;

Khoo, S .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S8-S14

[2]

BAKER J, AM J ADDICTIONS

[3] Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients [J].

Baker, JR ;

Best, AM ;

Pade, PA ;

McCance-Katz, EF .

ANNALS OF PHARMACOTHERAPY, 2006, 40 (03) :392-396

[4] Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors [J].

Baumann, P .

CLINICAL PHARMACOKINETICS, 1996, 31 (06) :444-469

[5] Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: A prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment [J].

Berk, Steven I. ;

Litwin, Alain H. ;

Arnsten, Julia H. ;

Du, Evelyn ;

Soloway, Irene ;

Gourevitch, Marc N. .

CLINICAL THERAPEUTICS, 2007, 29 (01) :131-138

[6] PROBABLE METABOLIC INTERACTION BETWEEN METHADONE AND FLUVOXAMINE IN ADDICT PATIENTS [J].

BERTSCHY, G ;

BAUMANN, P ;

EAP, CB ;

BAETTIG, D .

THERAPEUTIC DRUG MONITORING, 1994, 16 (01) :42-45

[7] Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects [J].

Bertschy, G ;

Eap, CB ;

Powell, K ;

Baumann, P .

THERAPEUTIC DRUG MONITORING, 1996, 18 (05) :570-572

[8]

BIAXIN, 2009, PHYS DESK REFERENCE, P411

[9] Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment [J].

Boffito, M ;

Rossati, A ;

Reynolds, HE ;

Hoggard, PG ;

Back, DJ ;

Di Perri, G .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (05) :341-342

[10] An in vitro approach to potential methadone metabolic-inhibition interactions [J].

Bomsien, Stephanie ;

Skopp, Gisela .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (09) :821-827

← 1 2 3 4 5 6 7 8 9 10 →